<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010902</url>
  </required_header>
  <id_info>
    <org_study_id>PreCoMS</org_study_id>
    <nct_id>NCT05010902</nct_id>
  </id_info>
  <brief_title>Pregnancy Cohort in Multiple Sclerosis (MS)</brief_title>
  <official_title>Pregnancy Cohort in Multiple Sclerosis (MS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the central&#xD;
      nervous system frequently affecting females in their reproductive phase of life. In this&#xD;
      prospective observational study, we obtain data on the outcome of pregnancies in MS patients&#xD;
      and the influence of pregnancy on clinical, laboratory and MRI parameters in MS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time until relapse</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Time (in days) until relapse during the observation period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of T2 lesions</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Number of T2 lesions in spinal and cerebral magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of gadolinium enhancing lesions</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Number of gadolinium enhancing lesions in spinal and cerebral magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of T2 lesions</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Volume of T2 lesions in spinal and cerebral magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of gadolinium enhancing lesions</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Volume of gadolinium enhancing lesions in spinal and cerebral magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in immune cell phenotypes</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Change in immune cell phenotypes of peripheral blood mononuclear cells (PBMC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Galectin-1</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Change in serum galectin-1 concentration measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Galectin-3</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Change in serum galectin-3 concentration measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Galectin-9</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Change in serum galectin-9 concentration measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurofilament (NfL)</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Change in neurofilament serum concentration by using Simoa NfL assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pro-inflammatory interleukin-17</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Change in interleukin-17 serum concentration assessed by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-inflammatory interleukin-10</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Change in anti-inflammatory interleukin-10 serum concentration assessed by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autoantibody profiling</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Identification and quantification of autoantibodies by using protein microarray and ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiome composition</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Composition of fecal microbiome measured by 16S Sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thickness of the retinal nerve fibre layer</measure>
    <time_frame>12 months after delivery (compared to baseline)</time_frame>
    <description>Thickness of the retinal nerve fibre layer by Optical Coherence Tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total macular volume (TMV)</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Total macular volume by Optical Coherence Tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-International Neuropsychiatric Interview (M.I.N.I.) German Version 5.0.0 Module A-C</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Structured diagnostic interview to assess depression, dysthymia and suicidality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Rating of ten depression related symptoms on a scale from 0 to 6 (higher numbers indicate more severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI-II)</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Rating of 21 depression related symptoms on a scale from 0 to 3 (higher numbers indicate more severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edinburgh Postpartum Depression Scale (EPDS)</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Self-report survey containing 10 items, each item is rated 0-3 (higher scores indicate a higher probability of postpartum depression)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Fatigue Inventory Scale (MFIS)</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>Self-report survey containing 21 items, each item is rated 0-4 (higher scores indicate a greater impact of fatigue on a person's activities)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale (FSS)</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>A self-report survey consisting of 11 items, each item ranges from 1 to 7 (higher scores indicate higher levels of fatigue)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Fatigue Analogue Scale (VFAS)</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>A self-administered, single scale indication measuring visual fatigue, ranging from 0 to 100 (higher scores indicate worse fatigue)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form Health Survey (SF-36)</measure>
    <time_frame>12 months after delivery compared to baseline</time_frame>
    <description>A self-report survey measuring health in eight dimensions (higher scores indicate less disability)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Sclerosis (MS)</condition>
  <condition>Clinically Isolated Syndrome (CIS)</condition>
  <arm_group>
    <arm_group_label>Multiple sclerosis</arm_group_label>
    <description>Patients with clinically isolated syndrome, relapsing-remitting or progressive multiple sclerosis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool and blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruted at neurological outpatient clinics and neurological clinics of&#xD;
        the Charité and neurologists' medical practices.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  diagnosis of multiple sclerosis or clinically isolated syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  clinically relevant comorbidities&#xD;
&#xD;
          -  contraindications for MRI, e.g. pacemaker, metal implants, allergy against gadolinium&#xD;
&#xD;
          -  alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anja Mähler, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Experimental &amp; Clinical Research Unit, Charité Universitätsmedizin Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadja Siebert, MD</last_name>
    <email>nadja.siebert@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Friedemann Paul, Prof.</last_name>
    <email>friedemann.paul@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadja Siebert, MD</last_name>
      <email>nadja.siebert@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Anja Maehler</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results of reported articles (text, tables, figures, supplemental data) will be shared after deidentification</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

